GenSight Biologics Raises EUR1.1 Million From Existing Investors

MT Newswires · 2d ago
03:32 AM EST, 11/20/2026 (MT Newswires) -- GenSight Biologics (SIGHT.PA) raised 1.1 million euros from existing shareholders Heights Capital and Invus, according to a Friday filing. The French biopharmaceutical company issued 4,237,288 ordinary shares, 13,157,898 pre-funded warrants and 17,395,186 warrants, each two of which can be exercised for one ordinary share. Net proceeds from the investments will fund operating activities and working capital requirements, potentially extending the company's cash runway through late March 2027. GenSight expects additional proceeds of 930,000 euros if all the warrants are exercised.